Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NascaCell Technologies AG

www.nascacell.de

Latest From NascaCell Technologies AG

Executive Briefing - Oligonucleotide therapeutics: the next big thing

1953 was an extraordinary year for biology, an annus mirabilis, or wonder year, which offered scientific insights to rival those made by Einstein almost half a century earlier.

Metabolic Disorders Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • NascaCell IP GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • NascaCell Technologies AG
  • Senior Management
  • Ernst Bohnlein, PhD, CEO
    Michael Blind, CSO
  • Contact Info
  • NascaCell Technologies AG
    Phone: (49) 89 54 72 72 - 0
    Max-Lebsche-Platz 31
    Munich, 81377
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register